SXTC
Income statement / Annual
Last year (2024), China SXT Pharmaceuticals, Inc.'s total revenue was $1.93 M,
a decrease of 2.19% from the previous year.
In 2024, China SXT Pharmaceuticals, Inc.'s net income was -$3.10 M.
See China SXT Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
| Operating Revenue |
$1.93 M |
$1.97 M |
$2.60 M |
$4.78 M |
$5.16 M |
$7.01 M |
$7.02 M |
$4.88 M |
$3.72 M |
| Cost of Revenue |
$1.37 M
|
$1.55 M
|
$1.35 M
|
$1.94 M
|
$2.46 M
|
$2.40 M
|
$3.62 M
|
$2.57 M
|
$2.92 M
|
| Gross Profit |
$553.97 K
|
$426.27 K
|
$1.25 M
|
$2.84 M
|
$2.70 M
|
$4.61 M
|
$3.40 M
|
$2.31 M
|
$793.99 K
|
| Gross Profit Ratio |
0.29
|
0.22
|
0.48
|
0.59
|
0.52
|
0.66
|
0.48
|
0.47
|
0.21
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$2.64 M
|
$5.65 M
|
$5.52 M
|
$3.45 M
|
$2.46 M
|
$1.24 M
|
$1.26 M
|
$565.46 K
|
$433.82 K
|
| Selling & Marketing Expenses |
$433.57 K
|
$387.45 K
|
$924.54 K
|
$1.59 M
|
$1.58 M
|
$1.61 M
|
$512.48 K
|
$144.36 K
|
$151.03 K
|
| Selling, General & Administrative Expenses |
$3.07 M
|
$6.03 M
|
$6.44 M
|
$5.04 M
|
$4.04 M
|
$2.84 M
|
$1.77 M
|
$709.82 K
|
$584.85 K
|
| Other Expenses |
$0.00
|
$149.51 K
|
-$181.58 K
|
$871.65 K
|
-$73.77 K
|
$27.14 K
|
-$3.80 K
|
$18.40 K
|
$0.00
|
| Operating Expenses |
$3.07 M
|
$6.03 M
|
$6.44 M
|
$5.04 M
|
$4.04 M
|
$2.84 M
|
$1.77 M
|
$709.82 K
|
$584.85 K
|
| Cost And Expenses |
$4.44 M
|
$7.58 M
|
$7.79 M
|
$6.97 M
|
$6.50 M
|
$5.24 M
|
$5.39 M
|
$3.28 M
|
$3.51 M
|
| Interest Income |
$0.00
|
$476.78 K
|
$36.70 K
|
$1.11 M
|
$3.35 M
|
$5.17 K
|
$0.00
|
$0.00
|
$51.06 K
|
| Interest Expense |
$544.28 K
|
$476.78 K
|
$218.28 K
|
$1.62 M
|
$3.35 M
|
$5.17 K
|
$779.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$203.25 K
|
$250.16 K
|
$320.01 K
|
$345.41 K
|
$331.84 K
|
$180.92 K
|
$129.44 K
|
$99.23 K
|
$88.96 K
|
| EBITDA |
-$2.35 M |
-$5.21 M |
-$5.05 M |
-$1.85 M |
-$1.01 M |
$1.95 M |
$1.76 M |
$1.70 M |
$298.11 K |
| EBITDA Ratio |
-1.22
|
-2.64
|
-1.94
|
-0.39
|
-0.2
|
0.28
|
0.25
|
0.35
|
0.08
|
| Operating Income Ratio |
-1.3
|
-2.84
|
-1.99
|
-0.46
|
0.83
|
0.25
|
0.23
|
0.33
|
0.06
|
| Total Other Income/Expenses Net |
-$583.32 K
|
-$327.26 K
|
-$218.28 K
|
-$743.79 K
|
-$9.05 M
|
$21.97 K
|
-$4.58 K
|
-$21.99 K
|
-$20.42 K
|
| Income Before Tax |
-$3.10 M
|
-$5.93 M
|
-$5.41 M
|
-$2.94 M
|
-$10.39 M
|
$1.79 M
|
$1.63 M
|
$1.58 M
|
$188.73 K
|
| Income Before Tax Ratio |
-1.61
|
-3.01
|
-2.08
|
-0.62
|
-2.01
|
0.26
|
0.23
|
0.32
|
0.05
|
| Income Tax Expense |
$0.00
|
$476.78 K
|
$328.15 K
|
-$192.68 K
|
-$101.72 K
|
$252.23 K
|
$440.10 K
|
$395.05 K
|
$47.18 K
|
| Net Income |
-$3.10 M
|
-$5.93 M
|
-$5.74 M
|
-$2.75 M
|
-$10.29 M
|
$1.54 M
|
$1.19 M
|
$1.19 M
|
$141.54 K
|
| Net Income Ratio |
-1.61
|
-3.01
|
-2.2
|
-0.58
|
-1.99
|
0.22
|
0.17
|
0.24
|
0.04
|
| EPS |
-3.57 |
-22.23 |
-137.92 |
-95.48 |
-832.08 |
149.67 |
0 |
0 |
0 |
| EPS Diluted |
-3.57 |
-22.23 |
-137.92 |
-95.48 |
-832.08 |
149.67 |
0 |
0 |
0 |
| Weighted Average Shares Out |
$867.42 K
|
$266.97 K
|
$41.59 K
|
$28.78 K
|
$12.36 K
|
$10.28 K
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$867.42 K
|
$266.97 K
|
$41.59 K
|
$28.78 K
|
$12.36 K
|
$10.28 K
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
